GlobeNewswire: Galena Biopharma, Inc. Contains the last 10 of 268 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:12:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/12/29/1276660/0/en/Galena-Biopharma-Inc-Stockholders-Approve-Business-Combination-with-SELLAS-Life-Sciences-Group-Ltd-Board-Sets-Reverse-Stock-Split-Ratio.html?f=22&fvtc=4&fvtv=13044Galena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse Stock Split Ratio2017-12-29T14:25:00Z<![CDATA[SAN RAMON, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE) (“Galena”) announced today that its stockholders approved nine proposals at the reconvened Special Meeting of Stockholders held at 9:00 a.m. Eastern Time on December 29, 2017, including all proposals necessary to approve the business combination transaction in which the businesses of Galena and SELLAS Life Sciences Group Ltd (“SELLAS”), are expected to be combined (the “Merger”). One proposal, regarding approval of an amendment to Galena’s Certificate of Incorporation to allow the Galena board of directors to approve amendments to Galena’s bylaws, was not approved. The failure of stockholders to approve this proposal has no impact on the Merger.]]>https://www.globenewswire.com/news-release/2017/12/14/1262343/0/en/Galena-Will-Adjourn-Special-Meeting-until-Friday-December-29-2017-Urges-Stockholders-to-Vote.html?f=22&fvtc=4&fvtv=13044Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote2017-12-14T22:03:38Z<![CDATA[SAN RAMON, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), (“Galena”) announced today that its special meeting of stockholders (“Special Meeting”), scheduled for December 15, 2017, will be convened and adjourned, without any business being conducted, in order to allow sufficient time for stockholders to vote based upon a change in information regarding the discretionary authority of brokers to vote shares on Proposal 3 (the Reverse Stock Split Proposal) as described below. The Special Meeting will be adjourned to 9:00 a.m. local time on Friday, December 29, 2017, at the offices of Paul Hastings LLP, 200 Park Avenue, New York, New York 10166, to allow additional time for stockholders to vote on the proposals set forth in Galena’s proxy statement/prospectus/consent solicitation statement dated November 6, 2017 and filed with the Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(3) on November 8, 2017 (the “Proxy Statement/Prospectus/Consent Solicitation Statement”), including approval of the matters necessary to complete a business combination transaction in which the businesses of Galena and SELLAS Life Sciences Group Ltd, will be combined (the “Merger”). The Proxy Statement/Prospectus/Consent Solicitation Statement was previously supplemented by a supplement dated November 29, 2017 and filed with the SEC pursuant to Rule 424(b)(3) on November 30, 2017.]]>https://www.globenewswire.com/news-release/2017/12/08/1250418/0/en/Galena-Biopharma-Reminds-Shareholders-to-Vote-Ahead-of-Special-Meeting-on-December-15-2017.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 20172017-12-08T19:50:37Z<![CDATA[SAN RAMON, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE) would like to remind stockholders to vote their respective shares and support the business combination transaction with SELLAS Life Sciences Group Ltd. To assist stockholders, Galena has published a presentation on its website to provide an overview of the transaction and the proposals. The presentation can be accessed under Investors — Investor Resources, or by clicking here.]]>https://www.globenewswire.com/news-release/2017/11/09/1178997/0/en/Galena-Biopharma-Reports-Third-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Reports Third Quarter 2017 Financial Results2017-11-09T21:30:00Z<![CDATA[SAN RAMON, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial results for the quarter ended September 30, 2017.]]>https://www.globenewswire.com/news-release/2017/09/28/1134264/0/en/Galena-Biopharma-Announces-Completion-of-Enrollment-in-Two-NeuVax-nelipepimut-S-Clinical-Trials-in-Combination-with-Trastuzumab.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Announces Completion of Enrollment in Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab2017-09-28T11:05:00Z<![CDATA[Interim efficacy analysis expected in Q1, 2018 for Phase 2b in HER2 1+/2+ patients Interim efficacy analysis expected in Q1, 2018 for Phase 2b in HER2 1+/2+ patients]]>https://www.globenewswire.com/news-release/2017/09/11/1117399/0/en/Galena-Biopharma-and-BioVascular-Inc-Reaffirm-GALE-401-Partnership.html?f=22&fvtc=4&fvtv=13044Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership2017-09-11T11:05:00Z<![CDATA[SAN RAMON, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today announced it has reaffirmed its partnership with BioVascular, Inc. regarding the development of GALE-401. Working in conjunction with SELLAS Life Sciences, Galena’s proposed merger candidate, BioVascular has withdrawn its notice of termination, and]]>https://www.globenewswire.com/news-release/2017/08/14/1084530/0/en/Galena-Biopharma-Reports-Second-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Reports Second Quarter 2017 Financial Results2017-08-14T20:30:00Z<![CDATA[SAN RAMON, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial results for the quarter ended June 30, 2017.]]>https://www.globenewswire.com/news-release/2017/08/08/1081414/0/en/Galena-Biopharma-Enters-into-Merger-Agreement-with-SELLAS-Life-Sciences-Group.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group2017-08-08T10:00:00Z<![CDATA[SAN RAMON, Calif. and HAMILTON, Bermuda, and NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE) and SELLAS Life Sciences Group Ltd, a privately-held, oncology-focused, clinical stage biopharmaceutical company, today jointly announced they have entered into an all stock definitive merger agreement under which SELLAS will merge into and become an indirect, wholly-owned subsidiary of Galena. The combined company will be renamed SELLAS Life Science Group, Inc. The merger will result in a combined company focused on the development of novel treatments for cancer.]]>https://www.globenewswire.com/news-release/2017/07/12/1042900/0/en/Galena-Biopharma-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Provides Corporate Update2017-07-12T10:30:00Z<![CDATA[SAN RAMON, Calif., July 12, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today announced an update on the status of the Company and its most advanced clinical development program.]]>https://www.globenewswire.com/news-release/2017/05/10/982116/0/en/Galena-Biopharma-Reports-First-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=13044Galena Biopharma Reports First Quarter 2017 Financial Results2017-05-10T20:30:00Z<![CDATA[SAN RAMON, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial results for the quarter ended March 31, 2017.]]>